Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 67%
Buy 22%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Liquidia is positioned for success in the biopharmaceutical industry with its unique PRINT technology, which has the potential to improve drug delivery to the lungs. The company's lead product candidate, Yutrepia, has shown strong performance in clinical trials and has the potential to become the best-in-class inhaled treprostinil treatment for pulmonary hypertension. Additionally, the company's upcoming study plans and development of L606 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) further support its growth potential. However, legal challenges to Yutrepia's freedom to operate and competition within the market remain risks to consider.

Bears say

Liquidia is a biopharmaceutical company that develops and manufactures drugs for pulmonary hypertension (PH) and interstitial lung disease (ILD). While the recently completed 24-week ASCENT study showed positive results for its inhaled treprostinil product, Yutrepia, there is still a lack of robust studies supporting its use in PH-ILD. Furthermore, the ongoing legal challenges to Yutrepia's freedom to operate could significantly impair Liquidia's ability to launch and sell its product, leading to potential financial penalties. These risks, combined with United Therapeutics' established position in the market and potential legal threats, make for a negative outlook on Liquidia's stock.

LQDA has been analyzed by 9 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 9 analysts, LQDA has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.